Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tyrosine-protein phosphatase non-receptor type 1 and type 2 (PTP1B and TC-PTP)
- Target
- PTP1B and TC-PTP
- Molecular classification
- Enzyme, Non-receptor protein tyrosine phosphatase
01
Overview
Tyrosine-protein phosphatase non-receptor type 1 (PTPN1, also known as protein-tyrosine phosphatase 1B or PTP1B) and type 2 (PTPN2, also known as TC-PTP) are intracellular enzymes regulating phosphorylation states of proteins involved in critical signaling cascades. PTPN1 acts as a negative regulator in insulin signaling, making it a drug target for type 2 diabetes and cancer. PTPN2 modulates inflammatory signaling and is implicated in cardiovascular disease and inflammation. Inhibition of these targets may alter immune responses and metabolic pathways, with dual inhibition (PTPN1/2) showing promise in anti-tumor immunity, though safety and off-target risks warrant careful consideration[1][2][3].
- Other names
- Protein tyrosine phosphatase 1BPTP1BT-cell protein-tyrosine phosphataseTC-PTP
02
Mechanism of action
Inhibition of PTPN1/2 leads to enhanced insulin signaling, anti-tumor immunity via T cell activation, and modulation of immune-related pathways. Dephosphorylation of receptor tyrosine kinases.
03
Biological functions
Signal transduction regulationNegative regulation of insulin signalingRegulation of inflammatory signaling pathwaysCell proliferationCell differentiationImmune response modulationEndoplasmic reticulum stress response
04
Disease associations
Type 2 diabetesCancer (including breast cancer, colorectal cancer, and other tumors)AtherosclerosisInflammatory diseasesCardiovascular disease
05
Safety considerations
Metabolic dysregulation (risk of hypoglycemia if insulin signaling is overly enhanced)Immune-related adverse events due to enhanced T cell activityPotential off-target effects and modulation of multiple signaling pathways
06
Interacting drugs
ABBV-CLS-484
1 more in the full profile.
07
Biomarkers
PTPN1/2 protein expression levels may be used to monitor insulin resistance, tumor progression, or inflammatory states
Beyond the preview
Go deeper on Tyrosine-protein phosphatase non-receptor type 1 and type 2 (PTP1B and TC-PTP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyrosine-protein phosphatase non-receptor type 1 and type 2 (PTP1B and TC-PTP).